Abstract | BACKGROUND: METHODS: Primary data on 726 premenopausal women (183 invasive breast cancer cases and 543 controls) and 1,108 postmenopausal women (385 invasive breast cancer cases and 723 controls) were analyzed. Urinary estrogen metabolites were measured using enzyme linked immunosorbent assays. Study-specific and combined multivariable adjusted odds ratios ( ORs) and 95% confidence intervals (CIs) were estimated based on tertiles of estrogen metabolites. Multinomial logistic regression models were fit according to hormone receptor status.
RESULTS: Higher premenopausal 2:16α-OHE1 was suggestive of reduced breast cancer risk overall (study-adjusted ORIIIvsI=0.80; 95% CI: 0.49-1.32) and for estrogen receptor negative (ER-) subtype (ORIIIvsI=0.33; 95% CI: 0.13-0.84). Among postmenopausal women, 2:16α-OHE1 was unrelated to breast cancer risk (study-adjusted ORIIIvsI=0.93; 95% CI: 0.65-1.33); however, the association between 2-OHE1 and risk varied by body mass index (p-interaction=0.003). CONCLUSIONS: Premenopausal urinary 2:16α-OHE1 may play a role in breast carcinogenesis; however, larger studies are needed. Our findings do not support reduced breast cancer risk with higher postmenopausal 2:16α-OHE1 overall, although obesity may modify associations with 2-OHE1.
|
Authors | Cher M Dallal, Roslyn A Stone, Jane A Cauley, Roberta B Ness, Victor G Vogel, Ian S Fentiman, Jay H Fowke, Vittorio Krogh, Steffen Loft, Elaine N Meilahn, Paola Muti, Anja Olsen, Kim Overvad, Sabina Sieri, Anne Tjønneland, Giske Ursin, Anja Wellejus, Emanuela Taioli |
Journal | The International journal of biological markers
(Int J Biol Markers)
Vol. 28
Issue 1
Pg. 3-16
(Apr 23 2013)
ISSN: 1724-6008 [Electronic] United States |
PMID | 22865302
(Publication Type: Journal Article, Meta-Analysis)
|
Chemical References |
- Biomarkers, Tumor
- Estrogens
- Estriol
|
Topics |
- Biomarkers, Tumor
(urine)
- Breast Neoplasms
(urine)
- Carcinoma, Ductal, Breast
(urine)
- Case-Control Studies
- Estriol
(urine)
- Estrogens
(urine)
- Female
- Humans
- Odds Ratio
- Postmenopause
- Premenopause
- Risk
|